Marco Fava

Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study

A. Gori, A. Bandera, M. Carrabba, 2022, Biomedicines.

Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort

A. d’Arminio Monforte, S. Lazzaroni, M. Valsecchi, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Mucormycosis in CAPA, a Possible Fungal Super-Infection

M. Mantero, F. Blasi, A. Gori, 2021, Journal of fungi.

Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment

D. Girelli, G. Grasselli, A. Pesenti, 2021, Internal and Emergency Medicine.

Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients

A. Gori, A. Bandera, M. Carrabba, 2023, Biomedicines.